Muscarinic antagonists in early stage clinical development for the treatment of asthma

References

• Owens MW, George RB. Nebulized atropine sulfate in the treatment of acute asthma. Chest. 1991;99:1084–1087.
   PubMed Web of Science ®Google Scholar
• Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med. 1987;82:59–64.
   PubMed Web of Science ®Google Scholar
• von Mutius E, Drazen JM. A patient with asthma seeks medical advice in 1828, 1928, and 2012. N Engl J Med. 2012;366:827–834.
   PubMed Web of Science ®Google Scholar
• Morris HG. Review of ipratropium bromide in induced bronchospasm in patients with asthma. Am J Med. 1986;81:36–44.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Sutter ME, Chan AL. The acute management of asthma. Clin Rev Allergy Immunol. 2015;48:114–125.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;8:CD000060.
   PubMed Web of Science ®Google Scholar
• Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Paediatr Respir Rev. 2013;14:234–235.
   PubMed Web of Science ®Google Scholar
• USA FDA. FDA Access Data. 2016 Aug 1. Available from: https://www.accessdata.fda.gov/
   Google Scholar
• Gross NJ. Anticholinergic agents in asthma and COPD. Eur J Pharmacol. 2006;533:36–39.
   PubMed Web of Science ®Google Scholar
• Lulling J, Delwiche JP, Prignot J. Early bronchodilating effect of oxitropium bromide in comparison with ipratropium bromide. Respiration. 1981;42:188–192.
   PubMed Web of Science ®Google Scholar
• Beakes DE. The use of anticholinergics in asthma. J Asthma. 1997;34:357–368.
   PubMed Web of Science ®Google Scholar
• Larsson K. Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma. Respiration. 1982;43:57–63.
   PubMed Web of Science ®Google Scholar
• Wilson NM, Green S, Coe C, et al. Duration of protection by oxitropium bromide against cholinergic challenge. Eur J Respir Dis. 1987;71:455–458.
   PubMedGoogle Scholar
• Sposato B, Barzan R, Calabrese A, et al. Comparison of the protective effect amongst anticholinergic drugs on methacholine-induced bronchoconstriction in asthma. J Asthma. 2008;45:397–401.
   PubMed Web of Science ®Google Scholar
• Peel ET, Anderson G, Cheong B, et al. A comparison of oxitropium bromide and ipratropium bromide in asthma. Eur J Respir Dis. 1984;65:106–108.
   PubMedGoogle Scholar
• Pauwels JH, Desager KN, Creten WL, et al. Study of the bronchodilating effect of three doses of nebulized oxitropium bromide in asthmatic preschool children using the forced oscillation technique. Eur J Pediatr. 1997;156:329–332.
   PubMed Web of Science ®Google Scholar
• Shioya T, Kagaya M, Onodera A, et al. Effectiveness of the anticholinergic agent oxitropium bromide in elderly patients with bronchial asthma. Arzneimittelforschung. 1996;46:1130–1133.
   PubMed Web of Science ®Google Scholar
• Van Bever HP, Desager KN, Pauwels JH, et al. Comparison of the bronchodilating effect of oxitropium bromide and fenoterol in asthmatic children. Eur J Pediatr. 1994;153:604–606.
   PubMed Web of Science ®Google Scholar
• Nishi K, Fujimura M, Myou S, et al. Comparison of the bronchodilator activities of oxitropium bromide, fenoterol, and their combination in patients with chronic obstructive pulmonary disease and bronchial asthma. Clin Auton Res. 1993;3:41–44.
   PubMedGoogle Scholar
• Nakano Y, Enomoto N, Kawamoto A, et al. Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma. J Allergy Clin Immunol. 2000;106:472–478.
   PubMed Web of Science ®Google Scholar
• Kamei T, Fujita J, Okada H, et al. Comparison between fenoterol and fenoterol plus oxitropium bromide delivered by metered-dose inhaler with InspirEase to relieve acute asthma attack. J Asthma. 1999;36:67–75.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention. ginasthma.org. 2016.
   Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015;58:4131–4164.
   PubMed Web of Science ®Google Scholar
• Buels KS, Fryer AD. Muscarinic receptor antagonists: effects on pulmonary function. Handb Exp Pharmacol. 2012;208:317–341.
   Google Scholar
• Pera T, Penn RB. Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol. 2014;16:72–81.
   PubMed Web of Science ®Google Scholar
• Meurs H, Oenema TA, Kistemaker LE, et al. A new perspective on muscarinic receptor antagonism in obstructive airways diseases. Curr Opin Pharmacol. 2013;13:316–323.
   PubMed Web of Science ®Google Scholar
• Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
   PubMed Web of Science ®Google Scholar
• Kistemaker LE, Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol Sci. 2015;36:164–171.
   PubMed Web of Science ®Google Scholar
• Kume H, Fukunaga K, Oguma T. Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and beta2-adrenergic intrinsic efficacy. Pharmacol Ther. 2015;156:75–89.
   PubMed Web of Science ®Google Scholar
• Liu YH, Wu SZ, Wang G, et al. A long-acting beta2-adrenergic agonist increases the expression of muscarine cholinergic subtype3 receptors by activating the beta2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cells. Mol Med Rep. 2015;11:4121–4128.
   PubMed Web of Science ®Google Scholar
• Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol. 2011;163:44–52.
   PubMed Web of Science ®Google Scholar
• Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345:260–270.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol. 2011;128:308–314.
   PubMed Web of Science ®Google Scholar
• O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med. 1996;154:876–880.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Engel M, Moroni-Zentgraf P, et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study. Respir Med. 2014;108:1268–1276.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Moroni-Zentgraf P, Ablinger O, et al. Tiotropium Respimat(R) in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res. 2014;15:61.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–1207.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–1726.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3:367–376.
   PubMed Web of Science ®Google Scholar
• Vogelberg C, Moroni-Zentgraf P, Leonaviciute-Klimantaviciene M, et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20.
   PubMed Web of Science ®Google Scholar
• Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo-controlled study. PLoS One. 2015;10:e0124109.
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial. Clin Ther. 2015;37:418–426.
   PubMed Web of Science ®Google Scholar
• Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study. Clin Ther. 2014;36:526–533.
   PubMed Web of Science ®Google Scholar
• Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat(®) 5 mug is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109:329–338.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102:50–56.
   PubMed Web of Science ®Google Scholar
• Fardon T, Haggart K, Lee DK, et al. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir Med. 2007;101:1218–1228.
   PubMed Web of Science ®Google Scholar
• Park HW, Yang MS, Park CS, et al. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy. 2009;64:778–783.
   PubMed Web of Science ®Google Scholar
• Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;132:1068-1074.e1.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Kornmann O, Schmidt P, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011;128:315–322.
   PubMed Web of Science ®Google Scholar
• Terzano C, Petroianni A, Ricci A, et al. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness. Eur Rev Med Pharmacol Sci. 2004;8:259–264.
   PubMedGoogle Scholar
• Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs long-acting beta-agonist in combination with inhaled corticosteroids in black adults with asthma: the BELT randomized clinical trial. JAMA. 2015;314:1720–1730.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4:104–113 e102.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
   PubMed Web of Science ®Google Scholar
• Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax. 2010;65:39–43.
   PubMed Web of Science ®Google Scholar
• Finkelstein Y, Bournissen FG, Hutson JR, et al. Polymorphism of the ADRB2 gene and response to inhaled beta-agonists in children with asthma: a meta-analysis. J Asthma. 2009;46:900–905.
   PubMed Web of Science ®Google Scholar
• Asano K, Yamada-Yamasawa W, Kudoh H, et al. Association between beta-adrenoceptor gene polymorphisms and relative response to beta 2-agonists and anticholinergic drugs in Japanese asthmatic patients. Respirology. 2010;15:849–854.
   PubMed Web of Science ®Google Scholar
• Anderson DE, Kew KM, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev. 2015;8:CD011397.
   PubMedGoogle Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;1:CD011721.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2015;115:211–216.
   PubMed Web of Science ®Google Scholar
• Slovis CM, Daniels GM, Wharton DR. Intravenous use of glycopyrrolate in acute respiratory distress due to bronchospastic pulmonary disease. Ann Emerg Med. 1987;16:898–900.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax. 2015;70:519–527.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Macagno F, Valente S, et al. Inhaled muscarinic acetylcholine receptor antagonists for treatment of COPD. Curr Med Chem. 2013;20:1464–1476.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Suratt PM, Gal TJ, et al. Effect of inhaled glycopyrrolate and atropine in asthma. Precipitated by exercise and cold air inhalation. Chest. 1984;85:325–328.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128:1974–1979.
   PubMed Web of Science ®Google Scholar
• Schroeckenstein DC, Bush RK, Chervinsky P, et al. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol. 1988;82:115–119.
   PubMed Web of Science ®Google Scholar
• Walker F, Kaiser DL, Kowal MB, et al. Prolonged effect of inhaled glycopyrrolate in asthma. Chest. 1987;91:49–51.
   PubMed Web of Science ®Google Scholar
• Gilman MJ, Meyer L, Carter J, et al. Comparison of aerosolized glycopyrrolate and metaproterenol in acute asthma. Chest. 1990;98:1095–1098.
   PubMed Web of Science ®Google Scholar
• Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of asthma. Ann Emerg Med. 1994;23:270–274.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Macis G, et al. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016;21:1820–1827.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (NLM) at the National Institutes of Health (NIH). ClinicalTrials.gov. cited 2016 Aug 3. Available from: https://clinicaltrials.gov/ct2/home.
   Google Scholar
• Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870–881.
   PubMed Web of Science ®Google Scholar
• Albertson TE, Harper R, Murin S, et al. Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Prefer Adherence. 2015;9:235–242.
   PubMed Web of Science ®Google Scholar
• Cahn A, Mehta R, Preece A, et al. Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial. Clin Drug Investig. 2013;33:653–664.
   PubMed Web of Science ®Google Scholar
• Mehta R, Hardes K, Kelleher D, et al. Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther. 2014;36:1016–1027 e1012.
   PubMed Web of Science ®Google Scholar
• Brealey N, Gupta A, Renaux J, et al. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:753–764.
   PubMed Web of Science ®Google Scholar
• Yang S, Lee L, Mallett S, et al. A randomized, crossover study to investigate the pharmacokinetics and safety of inhaled fluticasone furoate and umeclidinium, administered separately and in combination via dry powder inhaler in healthy adult volunteers. Adv Ther. 2015;32:157–171.
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7:e50716.
   PubMed Web of Science ®Google Scholar
• Cahn A, Tal-Singer R, Pouliquen IJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Investig. 2013;33:477–488.
   PubMed Web of Science ®Google Scholar
• Hu C, Jia J, Dong K, et al. Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PloS One. 2015;10:e0121264.
   PubMed Web of Science ®Google Scholar
• Lee LA, Yang S, Kerwin E, et al. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study. Respir Med. 2015;109:54–62.
   PubMed Web of Science ®Google Scholar
• Lee LA, Briggs A, Edwards LD, et al. A randomized, three-period crossover study of umeclidinium as monotherapy in adult patients with asthma. Respir Med. 2015;109:63–73.
   PubMed Web of Science ®Google Scholar
• Yang S, Goyal N, Beerahee M, et al. Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma. Eur J Clin Pharmacol. 2015;71:1051–1058.
   PubMed Web of Science ®Google Scholar
• Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330:660–668.
   PubMed Web of Science ®Google Scholar
• Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009;331:740–751.
   PubMed Web of Science ®Google Scholar
• Price D, Fromer L, Kaplan A, et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med. 2014;24:14023.
   PubMed Web of Science ®Google Scholar
• Bulkhi A, Tabatabaian F, Casale TB. Long-acting muscarinic antagonists for difficult-to-treat asthma: emerging evidence and future directions. Drugs. 2016;76:999–1013.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439–1450.
   PubMed Web of Science ®Google Scholar
• Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380–390.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.
   PubMed Web of Science ®Google Scholar
• Tashkin DP. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14:1759–1772.
   PubMed Web of Science ®Google Scholar
• Celli B, Decramer M, Leimer I, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137:20–30.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Santini G, et al. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014;19:1928–1935.
   PubMed Web of Science ®Google Scholar